FDA grants Fast Track to Baxter JAK inhibitor

Share this article:

CTI Biopharma has scored a Fast Track designation for its JAK2 inhibitor pacritinib, CTI and its partner Baxter announced. The experimental drug is being reviewed for patients with intermediate or high-risk myelofibrosis. The pursued indication also includes patients with disease or treatment-induced thrombocytopenia, a state in which patients have low platelet levels.

The oral tyrosine kinase inhibitor is being reviewed based on the firm's Phase-III PERSIST trials. The companies said in a statement that pacritinib may have an edge over other JAK inhibitors because it appears to be associated with fewer cases of treatment-stimulated cases of thrombocytopenia.

CTI and Baxter partnered up last year in a worldwide license agreement in which both companies will commercialize the drug in the US, but Baxter will have full commercial rights everywhere else.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.